HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $15.01, but opened at $14.07. HUTCHMED shares last traded at $13.93, with a volume of 34,031 shares trading hands.
Analysts Set New Price Targets
Separately, StockNews.com cut HUTCHMED from a "buy" rating to a "hold" rating in a report on Monday, November 18th.
View Our Latest Research Report on HCM
HUTCHMED Stock Down 7.7 %
The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The business's fifty day moving average price is $16.06 and its 200 day moving average price is $17.71.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC increased its stake in HUTCHMED by 362.2% in the third quarter. Jane Street Group LLC now owns 62,997 shares of the company's stock valued at $1,305,000 after purchasing an additional 49,366 shares during the last quarter. State Street Corp boosted its position in shares of HUTCHMED by 0.9% in the third quarter. State Street Corp now owns 349,524 shares of the company's stock worth $6,826,000 after acquiring an additional 3,078 shares during the last quarter. Rhumbline Advisers grew its holdings in HUTCHMED by 8.1% in the second quarter. Rhumbline Advisers now owns 7,553 shares of the company's stock valued at $129,000 after purchasing an additional 564 shares during the period. M&G PLC increased its position in HUTCHMED by 98.1% during the third quarter. M&G PLC now owns 267,231 shares of the company's stock worth $5,345,000 after purchasing an additional 132,333 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in HUTCHMED by 638.2% during the third quarter. Blue Trust Inc. now owns 3,536 shares of the company's stock worth $69,000 after purchasing an additional 3,057 shares during the period. 8.82% of the stock is currently owned by institutional investors and hedge funds.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
